Richard E. Middleton

3.5k total citations · 1 hit paper
27 papers, 2.4k citations indexed

About

Richard E. Middleton is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Oncology. According to data from OpenAlex, Richard E. Middleton has authored 27 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 7 papers in Cellular and Molecular Neuroscience and 4 papers in Oncology. Recurrent topics in Richard E. Middleton's work include Ion channel regulation and function (13 papers), Nicotinic Acetylcholine Receptors Study (7 papers) and Protein Degradation and Inhibitors (4 papers). Richard E. Middleton is often cited by papers focused on Ion channel regulation and function (13 papers), Nicotinic Acetylcholine Receptors Study (7 papers) and Protein Degradation and Inhibitors (4 papers). Richard E. Middleton collaborates with scholars based in United States, United Kingdom and Switzerland. Richard E. Middleton's co-authors include Huahang Sun, Kwok‐Kin Wong, Christopher J. Ott, Gang Lu, William G. Kaelin, Constantine S. Mitsiades, James E. Bradner, Jonathan B. Cohen, Christopher Miller and Martin Köhler and has published in prestigious journals such as Nature, Science and Biochemistry.

In The Last Decade

Richard E. Middleton

26 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

2013 1.1k citations Gang Lu, Richard E. Middleton et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard E. Middleton United States	18	2.0k	524	386	374	228	27	2.4k
Donald J. Kyle United States	25	897 0.5×	107 0.2×	440 1.1×	115 0.3×	190 0.8×	59	1.7k
Stefan Dove Germany	30	1.5k 0.7×	94 0.2×	415 1.1×	162 0.4×	50 0.2×	75	2.1k
Peter Chase United States	24	1.2k 0.6×	67 0.1×	214 0.6×	221 0.6×	65 0.3×	68	2.0k
Mario A. Pagano Italy	29	1.9k 0.9×	118 0.2×	148 0.4×	368 1.0×	16 0.1×	70	2.8k
Eugenia Poliakov United States	19	1.6k 0.8×	103 0.2×	183 0.5×	62 0.2×	23 0.1×	47	2.4k
Marian B. Meyers United States	27	2.2k 1.1×	42 0.1×	375 1.0×	1.2k 3.2×	58 0.3×	39	3.1k
Guy Servant Canada	19	1.3k 0.7×	36 0.1×	341 0.9×	197 0.5×	297 1.3×	31	2.4k
Jason Witherington United Kingdom	26	928 0.5×	208 0.4×	116 0.3×	266 0.7×	17 0.1×	63	2.0k
Fabien Vincent United States	18	1.1k 0.5×	28 0.1×	148 0.4×	202 0.5×	256 1.1×	34	1.9k
J E Casnellie United States	33	2.2k 1.1×	53 0.1×	376 1.0×	390 1.0×	18 0.1×	42	3.1k

Countries citing papers authored by Richard E. Middleton

Since Specialization

Citations

This map shows the geographic impact of Richard E. Middleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard E. Middleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard E. Middleton more than expected).

Fields of papers citing papers by Richard E. Middleton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard E. Middleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard E. Middleton. The network helps show where Richard E. Middleton may publish in the future.

Co-authorship network of co-authors of Richard E. Middleton

This figure shows the co-authorship network connecting the top 25 collaborators of Richard E. Middleton. A scholar is included among the top collaborators of Richard E. Middleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard E. Middleton. Richard E. Middleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maxson, Julia E., Melissa L. Abel, Jinhua Wang, et al.. (2016). Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research. 76(1). 127–138. 26 indexed citations

Lu, Gang, Richard E. Middleton, Huahang Sun, et al.. (2013). The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science. 343(6168). 305–309. 1108 indexed citations breakdown →

Fischer, Christian, Susan L. Zultanski, Hua Zhou, et al.. (2012). Triazoloamides as potent γ-secretase modulators with reduced hERG liability. Bioorganic & Medicinal Chemistry Letters. 22(9). 3140–3146. 13 indexed citations

Townsend, Matthew, Yujie Qu, Audrey Gray, et al.. (2010). Oral Treatment with a γ-Secretase Inhibitor Improves Long-Term Potentiation in a Mouse Model of Alzheimer's Disease. Journal of Pharmacology and Experimental Therapeutics. 333(1). 110–119. 35 indexed citations

Fischer, Christian, Sanjiv Shah, Bethany Hughes, et al.. (2010). Quinazolinones as γ-secretase modulators. Bioorganic & Medicinal Chemistry Letters. 21(2). 773–776. 13 indexed citations

Rivkin, Alexey, Chaomin Li, Solomon D. Kattar, et al.. (2009). Piperazinyl pyrimidine derivatives as potent γ-secretase modulators. Bioorganic & Medicinal Chemistry Letters. 20(3). 1269–1271. 33 indexed citations

Heidebrecht, Richard W., Mélissa Chénard, William K. Dahlberg, et al.. (2009). Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2). Bioorganic & Medicinal Chemistry Letters. 19(7). 2053–2058. 17 indexed citations

Wilson, Kevin J., David J. Witter, Jonathan B. Grimm, et al.. (2008). Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1). Bioorganic & Medicinal Chemistry Letters. 18(6). 1859–1863. 20 indexed citations

Methot, Joey L., Christopher L. Hamblett, Joon Jung, et al.. (2008). SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorganic & Medicinal Chemistry Letters. 18(23). 6104–6109. 36 indexed citations

10.

Hubbs, Jed L., Hua Zhou, Astrid M. Kral, et al.. (2007). Amino acid derivatives as histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(1). 34–38. 15 indexed citations

11.

Rosenstein, Craig, et al.. (2007). Quality Control Procedures for Dose-Response Curve Generation Using Nanoliter Dispense Technologies. SLAS DISCOVERY. 12(6). 891–899. 15 indexed citations

12.

Priest, Birgit T., Randal M. Bugianesi, Paula M. Dulski, et al.. (2006). A High-Capacity Membrane Potential FRET-Based Assay for Na _V 1.8 Channels. Assay and Drug Development Technologies. 4(1). 37–48. 25 indexed citations

13.

Johnson, Daniel M., Elizabeth M. Garrett, A. Richard Rutter, et al.. (2006). Functional Mapping of the Transient Receptor Potential Vanilloid 1 Intracellular Binding Site. Molecular Pharmacology. 70(3). 1005–1012. 27 indexed citations

14.

Seabrook, Guy R., Kathy Sutton, Wolfgang Jarolimek, et al.. (2002). Functional Properties of the High-Affinity TRPV1 (VR1) Vanilloid Receptor Antagonist (4-Hydroxy-5-iodo-3-methoxyphenylacetate ester) Iodo-Resiniferatoxin. Journal of Pharmacology and Experimental Therapeutics. 303(3). 1052–1060. 108 indexed citations

15.

Bansal, Alka, et al.. (2001). Delay of Intracellular Calcium Transients Using a Calcium Chelator: Application to High-Throughput Screening of the Capsaicin Receptor Ion Channel and G-Protein-Coupled Receptors. Analytical Biochemistry. 294(1). 27–35. 8 indexed citations

16.

Middleton, Richard E., et al.. (1999). Photoaffinity Labeling the Torpedo Nicotinic Acetylcholine Receptor with [³H]Tetracaine, a Nondesensitizing Noncompetitive Antagonist. Molecular Pharmacology. 56(2). 290–299. 46 indexed citations

17.

Chiara, David C., Richard E. Middleton, & Jonathan B. Cohen. (1998). Identification of tryptophan 55 as the primary site of [³H]nicotine photoincorporation in the γ‐subunit of the Torpedo nicotinic acetylcholine receptor. FEBS Letters. 423(2). 223–226. 46 indexed citations

18.

Middleton, Richard E., et al.. (1996). Homodimeric architecture of a CIC-type chloride ion channel. Nature. 383(6598). 337–340. 216 indexed citations

19.

Middleton, Richard E., et al.. (1994). Purification, Reconstitution, and Subunit Composition of a Voltage-Gated Chloride Channel from Torpedo Electroplax. Biochemistry. 33(45). 13189–13198. 105 indexed citations

20.

Middleton, Richard E. & Jonathan B. Cohen. (1991). Mapping of the acetylcholine binding site of the nicotinic acetylcholine receptor: [3H]nicotine as an agonist photoaffinity label. Biochemistry. 30(28). 6987–6997. 173 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact